LONA:NASDAQ
LeonaBio Inc
US$ 2,87
0,00%
(0,00) 1D
28 de set., 16:00:00 GMT-4 · USD
search
Todos os ativos
1D
5D
1M
6M
YTD
1A
5A
MÁX
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para LONA…
Valor de mercado
27,04 mi
Volume médio
107,61 mil
Volume
120,00
Alto — 52 sem
US$ 14,21
Baixo — 52 sem
US$ 2,21
LPA
-US$ 19,72
Beta
2,05
Ações em circulação
9,42 mi
Nº de funcionários
19
Valor de mercado
27,04 mi
Volume médio
107,61 mil
Volume
120,00
Alto — 52 sem
US$ 14,21
Baixo — 52 sem
US$ 2,21
LPA
-US$ 19,72
Beta
2,05
Ações em circulação
9,42 mi
Nº de funcionários
19
Notícias
De fontes da web e parceiros de notícias
Benzinga
·
há 19 horas
12 Health Care Stocks Moving In Monday's Intraday Session
Perfil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Sobre LeonaBio Inc